Skip to main content
Premium Trial:

Request an Annual Quote

Metabolon, Charles River Partner on Cancer Research

NEW YORK (GenomeWeb News) –Metabolon and Charles River Discovery Services are partnering to advance cancer research.

The deal, which was officially announced this week, leverages Metabolon's metabolomics technology with Charles River's preclinical oncology expertise.

Together, they will provide customers services focused on identifying, characterizing, and validating drug target candidates; pharmacokinetic and pharmacodynamic, tumor growth delay, tumor growth inhibition, survival, combination, and adjuvant study designs; and development of biomarkers for preclinical pharmacodynamic work, patient stratification and selection, and translational models and efficacy.

Financial and other terms of the deal were not disclosed.

Metabolon is a metabolomics-based diagnostics and services firm. Charles River Discovery Services, part of Charles River Laboratories, provides products for early compound in vitro screening and differentiation.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.